Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophy.

Spinazzola JM, Kunkel LM.

Expert Opin Orphan Drugs. 2016;4(11):1179-1194. doi: 10.1080/21678707.2016.1240613. Epub 2016 Oct 18.

2.

Drug Discovery of Therapies for Duchenne Muscular Dystrophy.

Blat Y, Blat S.

J Biomol Screen. 2015 Dec;20(10):1189-203. doi: 10.1177/1087057115586535. Epub 2015 May 14. Review.

PMID:
25975656
3.

Pharmacologically targeting the primary defect and downstream pathology in Duchenne muscular dystrophy.

Fairclough RJ, Perkins KJ, Davies KE.

Curr Gene Ther. 2012 Jun;12(3):206-44. Review.

PMID:
22571500
4.

Emerging drugs for Duchenne muscular dystrophy.

Malik V, Rodino-Klapac LR, Mendell JR.

Expert Opin Emerg Drugs. 2012 Jun;17(2):261-77. doi: 10.1517/14728214.2012.691965. Review.

5.

Pharmacological prospects in the treatment of Duchenne muscular dystrophy.

Ruegg UT.

Curr Opin Neurol. 2013 Oct;26(5):577-84. doi: 10.1097/WCO.0b013e328364fbaf. Review.

PMID:
23995279
6.

Duchenne muscular dystrophy drug discovery - the application of utrophin promoter activation screening.

Moorwood C, Khurana TS.

Expert Opin Drug Discov. 2013 May;8(5):569-81. doi: 10.1517/17460441.2013.777040. Epub 2013 Mar 9. Review.

PMID:
23473647
7.

Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors.

Miyatake S, Shimizu-Motohashi Y, Takeda S, Aoki Y.

Drug Des Devel Ther. 2016 Aug 30;10:2745-58. doi: 10.2147/DDDT.S110163. eCollection 2016. Review.

8.

Evolving therapeutic strategies for Duchenne muscular dystrophy: targeting downstream events.

Tidball JG, Wehling-Henricks M.

Pediatr Res. 2004 Dec;56(6):831-41. Epub 2004 Nov 5. Review.

PMID:
15531741
9.

Combined Therapies for Duchenne Muscular Dystrophy to Optimize Treatment Efficacy.

Cordova G, Negroni E, Cabello-Verrugio C, Mouly V, Trollet C.

Front Genet. 2018 Apr 10;9:114. doi: 10.3389/fgene.2018.00114. eCollection 2018. Review.

10.

New developments in the use of gene therapy to treat Duchenne muscular dystrophy.

Jarmin S, Kymalainen H, Popplewell L, Dickson G.

Expert Opin Biol Ther. 2014 Feb;14(2):209-30. doi: 10.1517/14712598.2014.866087. Epub 2013 Dec 6. Review.

PMID:
24308293
11.

[Advances in the treatment of Duchenne muscular dystrophy].

Ortez C, Natera de Benito D, Carrera García L, Expósito J, Nolasco G, Nascimento A.

Medicina (B Aires). 2019;79 Suppl 3:77-81. Spanish.

12.

Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy.

Kemaladewi DU, Hoogaars WM, van Heiningen SH, Terlouw S, de Gorter DJ, den Dunnen JT, van Ommen GJ, Aartsma-Rus A, ten Dijke P, 't Hoen PA.

BMC Med Genomics. 2011 Apr 20;4:36. doi: 10.1186/1755-8794-4-36.

13.

Immune-mediated pathology in Duchenne muscular dystrophy.

Rosenberg AS, Puig M, Nagaraju K, Hoffman EP, Villalta SA, Rao VA, Wakefield LM, Woodcock J.

Sci Transl Med. 2015 Aug 5;7(299):299rv4. doi: 10.1126/scitranslmed.aaa7322. Review.

14.

Targeting fibrosis in Duchenne muscular dystrophy.

Zhou L, Lu H.

J Neuropathol Exp Neurol. 2010 Aug;69(8):771-6. doi: 10.1097/NEN.0b013e3181e9a34b. Review.

15.

Vascular-targeted therapies for Duchenne muscular dystrophy.

Ennen JP, Verma M, Asakura A.

Skelet Muscle. 2013 Apr 23;3(1):9. doi: 10.1186/2044-5040-3-9.

16.

Pharmacological strategies for muscular dystrophy.

Khurana TS, Davies KE.

Nat Rev Drug Discov. 2003 May;2(5):379-90. Review.

PMID:
12750741
17.

Systemic Antisense Therapeutics for Dystrophin and Myostatin Exon Splice Modulation Improve Muscle Pathology of Adult mdx Mice.

Lu-Nguyen N, Malerba A, Popplewell L, Schnell F, Hanson G, Dickson G.

Mol Ther Nucleic Acids. 2017 Mar 17;6:15-28. doi: 10.1016/j.omtn.2016.11.009. Epub 2016 Dec 10.

18.

Gene Therapy for Duchenne muscular dystrophy.

Ramos J, Chamberlain JS.

Expert Opin Orphan Drugs. 2015;3(11):1255-1266. Epub 2015 Oct 6.

19.

P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.

Sinadinos A, Young CN, Al-Khalidi R, Teti A, Kalinski P, Mohamad S, Floriot L, Henry T, Tozzi G, Jiang T, Wurtz O, Lefebvre A, Shugay M, Tong J, Vaudry D, Arkle S, doRego JC, Górecki DC.

PLoS Med. 2015 Oct 13;12(10):e1001888. doi: 10.1371/journal.pmed.1001888. eCollection 2015 Oct.

20.

Pharmacotherapy of Duchenne Muscular Dystrophy.

Hoffman EP.

Handb Exp Pharmacol. 2019 Aug 3. doi: 10.1007/164_2019_256. [Epub ahead of print]

PMID:
31375923

Supplemental Content

Support Center